drugset / Trial / NCT05438797
The Safety and Efficacy of Specific TIL-TCM Cells for Advanced Relapse-refractory or Metastatic Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
Clinical Study on the Safety and Efficacy of specific TIL-TCM cells for advanced relapse-refractory or metastatic pancreatic cancer.
Timeline
- Start
- 2021-04-02
- Primary completion
- 2024-04
- Completion
- 2024-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TIL-TCM | Cell therapy | 1e+09 cells | — |
| Subject | TIL-TCM | Cell therapy | 1e+10 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 15 mg/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 35 mg/kg | — |
| Background | Paclitaxel | Small molecule | 100 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 200 mg/m2 | — |